Aripiprazole long-acting injectable (ABILIFY MAINTENA) for treatment of schizophrenia

ABSTRACT Introduction: Patients with schizophrenia often relapse as a result of medication nonadherence. Methods: Long-acting injectable antipsychotics have been developed to improve medication adherence rates in this patient population. Results: Aripiprazole long-acting injection (LAI), branded Abilify Maintena®, received Food and Drug Administration approval for the treatment of schizophrenia in February of 2013. Aripiprazole LAI is the fourth intramuscular second-generation antipsychotic indicated for the treatment of schizophrenia. Discussion: This manuscript reviews important clinical information regarding its use as well as efficacy and tolerability data.

[1]  J. Kane,et al.  Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: An open-label, parallel-arm, multiple-dose study , 2013, Schizophrenia Research.

[2]  S. Potkin,et al.  Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole , 2013, Current medical research and opinion.

[3]  Alan B. Shafer,et al.  Causes of death and comparative mortality in Texas public mental health clients, 2006-2008 , 2013 .

[4]  J. Kane,et al.  Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia , 2013, Journal of medical economics.

[5]  S. Stahl,et al.  “Meta-guidelines” for the management of patients with schizophrenia , 2013, CNS Spectrums.

[6]  J. Kane,et al.  Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia , 2013, International clinical psychopharmacology.

[7]  J. Kane,et al.  Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. , 2012, The Journal of clinical psychiatry.

[8]  A. Newman-Tancredi,et al.  Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties , 2011, Psychopharmacology.

[9]  L. Boyer,et al.  Factors Associated with Medication Non-Adherence in Patients Suffering from Schizophrenia: A Cross-Sectional Study in a Universal Coverage Health-Care System , 2010 .

[10]  J. Haro,et al.  Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia , 2010, Psychiatry Research.

[11]  R. Conley,et al.  The cost of relapse and the predictors of relapse in the treatment of schizophrenia , 2010, BMC psychiatry.

[12]  D. Jeste,et al.  ACNP White Paper: Update on Use of Antipsychotic Drugs in Elderly Persons with Dementia , 2008, Neuropsychopharmacology.

[13]  S. Saha,et al.  A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? , 2007, Archives of general psychiatry.

[14]  John M Davis,et al.  Physical health monitoring of patients with schizophrenia. , 2004, The American journal of psychiatry.

[15]  M. Crismon,et al.  Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. , 2004, Clinical therapeutics.

[16]  J. Kane.  Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. , 2003, The Journal of clinical psychiatry.

[17]  Christian R. Dolder,et al.  Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. , 2002, The Journal of clinical psychiatry.

[18]  Kevin D Burris,et al.  Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors , 2002, Journal of Pharmacology and Experimental Therapeutics.

[19]  J. Guelfi,et al.  Guidelines for depot antipsychotic treatment in schizophrenia , 1998, European Neuropsychopharmacology.